Volumen: 17 # Number : Suplemento
Publication Date : Octubre Year: 2013
Authors: S.M. Ramadan, L. Cicconi, F. Lo-Coco
Abstract: The availability of several highly effective agents in acute promyelocytic leukemia (APL) including all-trans retinoic acid (ATRA), arsenic trioxide (ATO) and anthracyclines, has transformed this once highly fatal disease into the most frequently curable acute leukemia. While it is firmly established that neither autologous nor allogeneic stem cell transplantation (SCT) are indicated in first remission of the disease, and that patients relapsing after ATRA-containing regimens should be treated with ATO, controversy remains on the selection of the most appropriate consolidation therapy, and in particular on indications
for transplantation after second remission. Owing to the lack of randomized comparative studies
and the very limited number of relapses, consolidation
strategies should be based on several clinical and biological criteria and rely on both available reported
experience and published recommendations. These criteria include age and performance status, first remission duration, donor availability,
and minimal residual disease status. In this article, we review current recommendations and
controversial issues related to use of SCT in APL.
Key words:
Pages :
|
